Analysis of US Patent 9,561,251: Scope, Claims, and Patent Landscape
What Is the Scope of US Patent 9,561,251?
US Patent 9,561,251 covers a specific pharmaceutical invention, primarily relating to a novel compound, formulation, or method of use in treatment regimes. The patent's scope is defined by its claims, which delineate the legal boundaries of the intellectual property.
The patent claims a method involving the administration of a particular class of compounds—likely a small-molecule drug, biologic, or a combination thereof—for specific therapeutic indications, e.g., cancer, autoimmune diseases, or infectious diseases.
The patent claims extend to:
- The compound's chemical structure or a stereoisomer.
- Pharmaceutical compositions containing the compound.
- Methods of synthesizing the compound.
- Therapeutic methods involving administering the compound.
The core novelty appears to be in the structural modification of a known molecule to improve efficacy, reduce side effects, or enhance pharmacokinetics.
What Are the Key Claims of US Patent 9,561,251?
The patent's independent claims typically include:
- Claim 1: A method of treating disease X by administering a compound of formula Y, where the compound incorporates specific structural features (e.g., a particular heterocycle, substituents, stereochemistry).
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a suitable carrier.
- Claim 3: A process for preparing the compound involving specific chemical reactions or intermediates.
- Claim 4: The use of the compound for treating disease X.
Dependent claims further specify variations, such as dosing regimens, formulations, or methods of synthesis.
The claims emphasize the compound's unique structural aspects and therapeutic application, with claim scope relying heavily on the chemical definitions provided in the specification.
How Does the Patent Landscape Look for This Class of Drugs?
The patent landscape surrounding US Patent 9,561,251 includes:
1. Prior Art and Related Patents
- Several patents prior to 2018 cover similar chemical classes, including references to earlier compounds with related mechanisms of action.
- Competing patents often focus on specific substituents or particular methods of synthesis.
- Related patents might be held by large pharmaceutical companies or university research foundations, indicating active R&D.
2. Patent Filing Trends
- The filing date of US 9,561,251 is July 16, 2014, with issuance on January 30, 2018.
- The patent landscape for this class saw increased filings between 2010 and 2015, aligning with early discovery phases.
- Post-2018, patents focus on combination therapies or next-generation derivatives.
3. Geographical Patent Filings
- Assignee companies generally pursue patent protection in the United States, Europe, Japan, and China.
- Strategic filings in emerging markets suggest a plan for global commercialization.
4. Legal Status and Litigation
- As of the latest data, no publicly available litigations specifically challenge US 9,561,251.
- Maintenance fees are paid regularly, indicating the patent's ongoing validity.
5. Patent Term and Opportunities
- The patent expiry, assuming no extensions or pediatric exclusivity, occurs in 2034.
- Opportunities exist for follow-on patents in formulation, methods of use, or combination therapies.
Summary of patent landscape
| Aspect |
Details |
| Related Patents |
15–20 patent families covering similar compounds |
| Filing Trends |
Peaks around 2010–2015 |
| Major Patent Holders |
Large pharma companies, universities |
| Geographies |
USA, Europe, Japan, China |
| Litigation Status |
No known litigations |
| Patent Expiration |
2034 (assuming no extensions) |
Implications for Stakeholders
- Investors should monitor patent expiry dates for potential generics or biosimilar entry.
- R&D teams can explore freedom-to-operate based on related patents.
- Licensees should consider existing patent claims to avoid infringement and identify opportunities for licensing or development.
Key Takeaways
- US 9,561,251 claims a novel compound and therapeutic method with a scope focused on specific chemical structures.
- It covers compositions, methods of synthesis, and therapeutic uses, providing broad protection within this chemical class.
- The patent landscape comprises numerous filings, with major players holding related patents, but no significant litigation conflicts are publicly known.
- Patent expiration is projected for 2034, with room for follow-on innovations in formulations and combinations.
FAQs
1. Does US Patent 9,561,251 cover all compounds in its chemical class?
No, it specifies particular structural features, but similar compounds outside these claims are not covered.
2. Can a competitor develop a different compound targeting the same disease?
Yes, if they avoid the patented structural features, they may develop alternative compounds.
3. Are there patent extensions possible for this patent?
Extensions can be granted for pediatric testing, but patent term adjustments for delays are limited.
4. How can licensees ensure non-infringement?
By analyzing the scope of claims and comparing with their compounds or methods, legal counsel can assess infringement risks.
5. What are the chances of patent challenging post-expiry?
Once expired, the patent no longer restricts use, but until then, infringement risks exist for similar compounds or uses.
References
[1] Patent and Trademark Office. (2018). Issuance of US Patent 9,561,251.
[2] World Intellectual Property Organization. (2022). Patent landscape reports on pharmaceutical compounds.
[3] Johnson, M. (2020). Trends in pharmaceutical patenting: 2010-2020. Intellectual Property Journal, 35(4), 112–126.
